WHO ICTRP trial
Clinical Trial conduct to investigate if Daratumumab therapy for multiple…
EUCTR2017-003253-41-PL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-003253-41-PL |
|---|---|
| Public title | Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance or biochemical relapse is effective in preventive therapy. |
| Scientific title | PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR). - PREDATOR |
| Primary sponsor | Polish Myeloma Consortium |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Poland |
| Conditions | Multiple Myeloma and Minimal Residual Disease MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Darzalex® Product Name: Daratumumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DARATUMUMAB CAS Number: 945721-28-8 Other descriptive name: Daratumumab Concentration unit: mg/ml… |
| Registration date | Jun 8, 2018 |
| Target size | 274 |
| Secondary IDs | PMC008 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: